Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease

Pharmaceuticals

Anne Corbett¹  Gareth Williams¹ 

[1] Wolfson Centre for Age-Related Diseases, Guy’s Campus, King’s College London, London SE1 1UL, UK;

关键词: Alzheimer’s;    repositioning;    treatment;    drug;   

DOI  :  10.3390/ph6101304

来源: mdpi

【 摘 要 】

Alzheimer’s Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There is an urgent need to develop and evaluate more effective pharmacological treatments. Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches. This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date. Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.